Direxion Daily S&P Biotech Bull 3x Shares Rating $305.86 -5.95 (-1.91%) As of 09/3/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest Direxion Daily S&P Biotech Bull 3x Shares Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LABU Aggregate RatingModerate Buy 2.67Holdings in LABU have an aggregate rating of Moderate Buy based on 263 analyst ratings issued in the past year covering 15 companies (14.9% of the portfolio).LABU Aggregate Price Target$305.86High Prediction$305.86Average Prediction$305.86Low Prediction$305.86Holdings in LABU have an aggregate price target of $305.86 and a range of $305.86 to $305.86 covering 15 companies (14.9% of the portfolio).LABU Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Direxion Daily S&P Biotech Bull 3x Shares Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 15 LABU Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.89%MRNAModerna$148.87-1.3%1.476 of 5 stars2.08$76.72 -48.5%24Trending NewsAnalyst DowngradeInsider TradeOptions VolumeAnalyst RevisionGap Down1.29%TWSTTwist Bioscience$128.71-1.7%1.6563 of 5 stars2.70$98.30 -23.6%10Positive News1.01%ORKAOruka Therapeutics$90.99-0.7%2.8537 of 5 stars2.82$133.00 46.2%11Positive NewsAnalyst ForecastInsider Trade0.98%APGEApogee Therapeutics$135.10+0.0%1.5395 of 5 stars2.16$126.77 -6.2%19News CoverageHigh Trading Volume0.94%PRAXPraxis Precision Medicines$355.15-0.7%3.175 of 5 stars2.95$585.95 65.0%21Positive News0.92%HALOHalozyme Therapeutics$110.76+1.0%3.7885 of 5 stars2.62$91.20 -17.7%13Trending NewsAnalyst UpgradeAnalyst Revision0.92%KYMRKymera Therapeutics$117.28-1.1%1.8008 of 5 stars2.88$128.70 9.7%24News CoveragePositive NewsAnalyst Forecast0.92%NTRANatera$327.67+0.8%2.5024 of 5 stars2.82$319.38 -2.5%22Positive NewsInsider Trade0.87%RVMDRevolution Medicines$210.87+0.8%2.5075 of 5 stars2.95$200.74 -4.8%22Analyst ForecastInsider TradeAnalyst Revision0.87%CGONCG Oncology$74.33-0.3%3.2401 of 5 stars2.77$83.18 11.9%13Positive News0.87%DNTHDianthus Therapeutics$107.85+1.5%2.1778 of 5 stars2.93$124.27 15.2%14Positive NewsInsider Trade0.87%PTGXProtagonist Therapeutics$148.80+1.9%1.5329 of 5 stars2.89$147.13 -1.1%18Trending NewsAnalyst ForecastAnalyst Revision0.85%SYRESpyre Therapeutics$87.25+0.2%2.6118 of 5 stars2.87$109.69 25.7%15Trending NewsAnalyst ForecastInsider Trade0.84%TVTXTravere Therapeutics$66.54-1.0%1.6624 of 5 stars2.69$61.67 -7.3%13Positive News0.83%REGNRegeneron Pharmaceuticals$843.47-1.0%4.0657 of 5 stars2.58$800.36 -5.1%24Trending NewsInsider Trade This page (NYSEARCA:LABU) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bull 3x Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bull 3x Shares With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
